--- title: "Article 13a — Amendments to legacy contracts for the purpose of the implementation of benchmark reforms" type: regulation legal_status: in_force source: "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02012R0648-20250117" source_retrieved: 2026-10-11 shortTitle: "Article 13a — Amendments to legacy contracts for the purpose of the implementation of benchmark reforms" instrument_type: level1_regulation authority: Commission binding: true binding_character: binding mica_level2: false legal_basis: "Regulation (EU) No 648/2012" instrument: emir celex: "32012R0648" regulation: EMIR regulation-full: "Regulation (EU) No 648/2012" article: 13a status: in_force object_id: eu.emir.legal_text.article.13a text_version: "Consolidated version of 17 January 2025" source_url: "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02012R0648-20250117" check_status: matched verified: true last_checked: 2026-11-09 --- *In force · Consolidated version of 17 January 2025 · Verified 9 Nov 2026 · [Official source](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02012R0648-20250117)* 1. Counterparties may continue to apply the risk-management procedures referred to in Article 11(3) that they have in place on 13 February 2021 in respect of OTC derivative contracts which are not cleared by a CCP and that are entered into or novated before the date on which the obligation to have risk-management procedures in place pursuant to Article 11(3) takes effect where, after 13 February 2021, those contracts are subsequently amended or novated for the sole purpose of replacing a reference benchmark or introducing a fallback provision in relation to any benchmark referenced in that contract. 2. Contracts which are entered into or novated before the date on which the clearing obligation takes effect pursuant to Article 4 and which, after 13 February 2021, are subsequently amended or novated for the sole purpose of replacing a reference benchmark or introducing a fallback provision in relation to any benchmark referenced in that contract, shall not, for that reason, become subject to the clearing obligation referred to in Article 4. 3. Paragraphs 1 and 2 shall apply only to OTC derivative contracts the amendment or novation of which: **(a)** is necessary for the purpose of replacing a benchmark in the context of benchmark reforms; **(b)** does not change the economic substance or risk factor represented by the reference to a benchmark in such contract; and **(c)** does not encompass other changes to any legal term of that contract that does not relate to the benchmark referenced and thus potentially amends the contract in a way that effectively requires it to be considered a new contract. *** [Title II — Clearing, reporting and risk mitigation of OTC derivatives](../titles/ii.md) · [← Article 13](13.md) · [Article 14 →](14.md)